GIT Therapeutics

Company Overview

Snapshot

Founded in October 2024 by Erez Cohn, Avshalom Ben Manachem, and Ilan Zalit Zalit, GIT Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its proprietary TARDIS oral delivery system.

Business overview

GIT Therapeutics is a Health Tech & Life Sciences company focused on transforming oral drug delivery. The company's core technology is the proprietary TARDIS oral delivery system, designed to provide precise, sustained, and localized drug therapy within the digestive system. This system aims to maximize clinical efficacy, minimize side effects, and replace invasive therapies. GIT Therapeutics targets major multi-billion-dollar markets, including Parkinson’s disease, multiple sclerosis, inflammatory bowel disease (Crohn’s, Ulcerative Colitis), gastrointestinal infections, Celiac disease, and obesity management, operating within the Pharma & Medical Biotechnology and Drug Delivery sectors.

Company Intelligence Q&A

What is GIT Therapeutics' primary focus?

GIT Therapeutics is focused on redefining oral drug delivery through its proprietary TARDIS system, aiming to provide precise, sustained treatment directly within the digestive system.

When was GIT Therapeutics founded?

GIT Therapeutics was founded in October 2024.

Who are the founders of GIT Therapeutics?

The company was founded by Erez Cohn, Avshalom Ben Manachem, and Ilan Zalit Zalit.

What markets does GIT Therapeutics aim to address?

GIT Therapeutics aims to address critical unmet needs in major markets such as Parkinson’s disease, multiple sclerosis, inflammatory bowel disease, GI infections, Celiac disease, and obesity management.

What is the TARDIS oral delivery system?

The TARDIS oral delivery system is GIT Therapeutics' proprietary technology engineered to retain sustained-release drug therapy in specific gastrointestinal regions, such as the stomach or ileocecal valve, for a predefined time to enhance efficacy and safety.